Oxana Shatkovskaya

Dr. Oxana Shatkovskaya


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
AZAlma Zhylkaidarova
Alma Zhylkaidarova
Dilyara KaidarovaDilyara Kaidarova
Dilyara Kaidarova
KBKanat Batyrbekov
Kanat Batyrbekov
OSOxana Shatkovskaya
Oxana Shatkovskaya
DBDinara Begimbetova
Dinara Begimbetova
We carried out an analysis of the total incidence of colon cancer throughout Kazakhstan. Retrospectively, according to the regional reports on endoscopic screening, the study showed an increase in the age-related incidence of colorectal cancer (CRC) cases from 2004-2008 to 2009-2014. The peak of morbidity in both periods was noted in the age category of >70 years. The indicators of the territorial distribution of CRC incidence make it possible to divide the regions into areas with low or high rates of CRC. Specific indicators showed newly diagnosed cases of CRC stages I, II, III, and IV in 2004-2018. The incidence rates of stages I and II showed a two-fold increase (35%-67.4%) and the incidence of stage IV showed a decline from 19.3% to 13.1% and of stage III from 45.7% to 19.5% from 2004 to 2018, respectively. An analysis of CRC incidence throughout Kazakhstan showed an increase in the overall incidence. Since population-based CRC screening was introduced in 2011, the morbidity was found to increase for stages I and II.

25 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YSYuliya Semenova
Yuliya Semenova
ZBZhandos Burkitbayev
Zhandos Burkitbayev
NKNurtas Kalibekov
Nurtas Kalibekov
ADAlexandr Digay
Alexandr Digay
BZBakhyt Zhaxybayev
Bakhyt Zhaxybayev
AMAlmira Manatova
Almira Manatova
Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural mesothelioma is a primary malignancy of the pleura and occurs less often than metastatic pleural disease. Pleural malignancies often present with malignant pleural effusion, which typically indicates advanced-stage disease and is associated with poor overall prognosis. Treatment of pleural malignancies includes both palliative and definitive approaches. Palliative interventions primarily aim to relieve symptoms and improve quality of life. Definitive treatments include systemic chemotherapy, targeted therapy, and immunotherapy, depending on the type and molecular profile of the underlying tumor. In mesothelioma, platinum-based chemotherapy in combination with pemetrexed remains the cornerstone of treatment, while the combination of nivolumab and ipilimumab is recommended as first-line therapy for unresectable disease. For metastatic disease, systemic therapy is typically tailored to the primary tumor’s characteristics. Intrapleural administration of chemotherapeutic agents is one of the therapeutic strategies and hyperthermic intrathoracic chemotherapy and pressurized intrathoracic aerosol chemotherapy are the most recent innovations that are under active investigation. This review provides an up-to-date synthesis of systemic chemotherapy strategies for pleural malignancies, their integration with targeted and immune-based therapies, and recent advances in intrapleural chemotherapy modalities. It also explores existing knowledge gaps and outlines directions for future research and potential changes in clinical practice.

26 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YSYuliya Semenova
Yuliya Semenova
AKAltay Kerimkulov
Altay Kerimkulov
TUTalgat Uskenbayev
Talgat Uskenbayev
DZDinara Zharlyganova
Dinara Zharlyganova
OSOxana Shatkovskaya
Oxana Shatkovskaya
TATasbolat Adylkhanov
Tasbolat Adylkhanov
Cancers represent a significant global health burden, affecting millions of individuals each year

YSYuliya Semenova
Yuliya Semenova
ZBZhandos Burkitbayev
Zhandos Burkitbayev
SSSanzhar Shalekenov
Sanzhar Shalekenov
OSOxana Shatkovskaya
Oxana Shatkovskaya
GDGauhar Dunenova
Gauhar Dunenova
LPLyudmila Pivina
Lyudmila Pivina
Breast cancer (BC) is the most common cancer in Kazakhstan, and a population-based breast cancer screening program was introduced in 2008, initially targeting women aged 50–60 years. It was subsequently expanded in 2018 to include women aged 40–70 years. This study evaluates the national BC screening program from its introduction in 2008 onward, focusing on program outputs, outcomes, and associated expenditures. Several administrative datasets and official sources were analyzed, including the legislative acts database, analytical reports on cancer screening programs, and cancer reporting forms. Trends in key indicators were summarized using the average annual percent change (AAPC). From the program’s inception, the absolute number of women screened increased steadily, with an AAPC of 6.23%. In contrast, the proportion of eligible women covered by screening declined over time, particularly following the expansion of the target age groups in 2018. Stage I BC detected through screening accounted for only about 50% of all stage I BC cases diagnosed nationwide, while the contribution of screening to stage II cancers was below 30%. Neither the introduction nor the subsequent expansion of the BC screening program was associated with statistically significant immediate or trend changes in national BC incidence or mortality rates. These findings may inform evidence-based discussions on potential refinements to BC screening policy and practice in Kazakhstan.

31 December 2021 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Closed access
OSOxana Shatkovskaya
Oxana Shatkovskaya
Dilyara KaidarovaDilyara Kaidarova
Dilyara Kaidarova
ZDZaure Dushimova
Zaure Dushimova
MSM. Sagi
M. Sagi
RAR. Abdrakhmanov
R. Abdrakhmanov
Relevance: Globocan reported 4,390 new breast cancer cases and 1,654 deaths from breast cancer in the Republic of Kazakhstan (RK) in 2020. Molecular diagnostics of breast cancer includes the determination of Hormone Receptor (HR), HER2, and Ki-67 status to detect patients with HR-positive tumors and administer effective treatment. Methods: This observational study included a retrospective analysis of incidence, molecular diagnostics, and treatment regimens in women with a confirmed breast cancer diagnosis aged 18 years old and older, registered in the RK Electronic Registry of Cancer Patients (ERCP) from 1 January 2014 till 31 December 2019. Results: In the study period (2014 to 2019), the number of breast cancer cases registered annually has doubled. The incidence increased by 46.9%. The share of locally advanced and advanced forms of breast cancer has decreased. The proportion of Luminal type A (HR+/HER2-) among newly diagnosed patients ranged from 17.9% to 30%. Chemotherapy and endocrine therapy with goserelin, buserelin, leuprorelin, and fulvestrant are standard first- and second-line treatments for HR+ breast cancer. Since fulvestrant indications have been expanded, more than 50% of patients with HR-positive advanced breast cancer receive fulvestrant as the first-line therapy. Conclusion: Breast cancer incidence growth and a decrease in the share of locally advanced and advanced breast cancer cases in the RK could be attributed to increased coverage of eligible women aged 40 to 70 with breast cancer mammographic screening. Although international guidelines support the administration of hormone therapy with or without targeted therapy in women with HR-positive, HER2-metastatic breast cancer, upfront use of chemotherapy remains common in the RK even in the absence of visceral crisis. The use of CDK4/6 inhibitor palbociclib in combination with hormone therapy has become routinely available since 2019

31 March 2022 in Oncologia i Radiologia Kazakhstana
Verified
Journal Article
Open access
OSOxana Shatkovskaya
Oxana Shatkovskaya
Relevance: Drug supply is a prerequisite for drug treatment of malignant neoplasms. Drug therapy is an essential component of cancer treatment. The potential of drug therapy is not the same in different human tumors. Providing an oncological patient with a full range of modern medicines is one of the main tasks of the healthcare system. Currently, the problem of the availability of drug provision for cancer patients is relevant. Today, there is a regional disparity in the provision of drug care in the country: the availability of drugs for patients is highly dependent on the economic development of the region of their residence. Drugs, especially targeted and immuno-oncological drugs, are more available in the cities of republican significance and the capital city. The study aimed to analyze the problems and find ways to improve drug provision for cancer patients in the Republic of Kazakhstan. Methods included the analysis of the current drug provision for cancer patients in the Republic of Kazakhstan, identifying problematic issues, finding solutions, and developing correct unified approaches to determining the needs of cancer patients for drugs at all stages of care. The study results highlight the current problems of drug supply for cancer patients and allow the development of ways to improve it, including in the context of combating the COVID-19 pandemic. Conclusion: Breakthrough technologies and new regimens of cancer treatment appear almost every month. Therefore, it is essential to make balanced and rational decisions in this area, rather than applying simplified administrative schemes for orders and purchases. Today, the oncologists of Kazakhstan can choose therapy for each cancer patient when they possess the results of relevant molecular genetic studies, know the characteristics of the tumor and the body, and have а conclusion of the multidisciplinary team. All the above gives hope for a transition to a more humane attitude towards patients when the drug choice depends on the chosen therapy’s clinical efficacy and purposefulness instead of the drug origin or price. The damage from ineffective drugs often exceeds by far the cost of effective drugs and technologies, while these effective drugs will not always be the most expensive. It is a great art to choose the drug that a particular oncological patient needs.